Adjuvant Dabrafenib/Trametinib Approved in Europe for BRAF+ Melanoma

August 23, 2018 – The European Commission has approved the combination of dabrafenib and trametinib for the adjuvant treatment of patients with BRAF V600–positive stage III melanoma following complete resection, according to Novartis, the manufacturer of both agents. The approval is based on findings from the phase III COMBI-AD study, in which the primary analysis showed that adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or … (leggi tutto)